🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Daniel S.W. Tan

National Cancer Centre Singapore

ORCID: 0000-0002-6514-6786
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Table S2 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.22481301
Top 100%
0DataRank
Top 100%0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Papers

Driven by 14 papers — median percentile 0. Top paper: “Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study”.

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00247-3
N/A
5.0DataRank · unranked
445 citations

Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik +20 more

Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers

JCO Precision Oncology(2022)10.1200/po.21.00418
N/A
1.9DataRank · unranked
87 citations

Daniel S.W. Tan, Ulrik Lassen, Serge Leyvraz, Yongmei Liu, Jyoti D. Patel +10 more

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas

Cancer(2023)10.1002/cncr.35036
N/A
0.937DataRank · unranked
25 citations

Lin Shen, David S. Hong, Ray McDermott, Vicki L. Keedy, Michela Casanova +19 more

A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC)

EBioMedicine(2021)10.1016/j.ebiom.2021.103220
N/A
0DataRank · unranked
16 citations

Dawn Pingxi Lau, Xiaoqian Zhang, Xue-Lin Kwang, Neha Rohatgi, Jane Vin Chan +12 more

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Annals of Oncology(2022)10.1016/j.annonc.2022.08.002
N/A
0DataRank · unranked
181 citations

Giuseppe Curigliano, Michael Thomas, Vivek Subbiah, Christina S. Baik, Daniel S.W. Tan +21 more

Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001

Journal of Thoracic Oncology(2022)10.1016/j.jtho.2022.02.004
N/A
0DataRank · unranked
57 citations

Christian Rolfo, Alexander Drilon, Mario E. Lacouture, Benjamin Besse, Kōichi Goto +10 more

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer

Journal of Clinical Investigation(2022)10.1172/jci145099
N/A
0DataRank · unranked
57 citations

Wei Wu, Niki Karachaliou, Collin M. Blakely, Junji Suzuki, Yu‐Ting Chou +23 more

Data from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.c.6530655.v1
N/A
0DataRank · unranked
0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Supplementary Table S2 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.22481301
Top 100%
0DataRank
Top 100%0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Accelerating access to human genomics for public health: perspectives from the Western Pacific region

The Lancet Regional Health - Western Pacific(2024)10.1016/j.lanwpc.2024.101265
N/A
0DataRank · unranked
2 citations

Mengji Chen, Greco Mark Malijan, Dayoung Song, Anna Laura Ross, Elena Ambrosino +31 more

540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy

Annals of Oncology(2020)10.1016/j.annonc.2020.08.654
N/A
0DataRank · unranked
1 citations

Filippo de Braud, Alexander Drilon, Robert C. Doebele, Manish R. Patel, Byoung Chul Cho +15 more

Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects

Cancer Discovery(2025)10.1158/2159-8290.cd-24-1500
N/A
0DataRank · unranked
6 citations

David S.P. Tan, Anastasios Stathis, Geoffrey I. Shapiro, Satoru Iwasa, Markus Joerger +17 more

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.10.26.356352
N/A
0DataRank · unranked
1 citations

Wei Wu, Niki Karachaliou, Collin M. Blakely, Junji Suzuki, Siraj M. Ali +14 more

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.06.017
N/A
0DataRank · unranked
654 citations

Philip C. Mack, Giorgio V. Scagliotti, Charu Aggarwal, Maria E. Arcila, Fabrice Barlési +23 more